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Introduction
The use of peritoneal dialysis (PD) in the treatment of
patients with end-stage renal disease (ESRD) ﬂuctuates
considerably from country to country [1]. The propor-
tion varies from 0 to above 60% of the total dialysis
population and is most often explained by socio-
economic, health care or reimbursement factors [1–4].
This disparity, however, also exists at the regional or at
the centre level and may also change over time within
the same unit, meaning that other factors must play a
role. Based on the Swiss experience over the last few
years, the present review analyses those factors and
proposes some strategies towards a more homoge-
neous use of dialysis modalities.
Some facts about PD utilization
Over the past decade several studies have compared the
outcomes of PD vs haemodialysis (HD) and, despite
some conﬂicting reports, no major difference in patient
survival has been observed [5,6]. In addition, an
absolute medical contra-indication for one of those
therapies remains rare for the majority of patients who
have to start ESRD therapy [7]. PD has now been
proposed to become the initial part of an integrated
ESRF therapeutic plan [8,9].
These observations suggest that the choice of a
dialysis treatment modality is based on factors other
than the medical superiority of one technique over the
other. Some of the non-medical factors have been
identiﬁed, in particular within the USA [2,10]. In a
survey covering most European countries, the USA
and Japan, Gokal et al. [1] have shown that large
differences exist in the incidence and prevalence of
ESRF and in the distribution of the different treatment
modalities. The differences were attributed mostly to
the type of social security system: ‘public’ systems with
a low prevalence and incidence of ESRD and a
homogeneous distribution between HD, PD and
renal transplantation; ‘private’ systems with a high
prevalence, incidence and a main development of HD;
and the so-called ‘mixed’ systems with an intermediate
distribution pattern.
The existing regional and centre disparities, how-
ever, indicate that the distribution between HD and
PD therapies does not exclusively depend on the type
of social security system. Changes may also occur over
time as illustrated by the evolution in the number of
patients treated by chronic dialysis over the last 5 years
in Switzerland (Figure 1): the slow increase in the total
number of dialysis patients is almost exclusively due to
centre HD, while the PD patient numbers stabilized
but with more and more automated PD (APD)
treatments. While in 1993 PD was used in 18% of
the total Swiss dialysis population, this percentage has
declined and now stabilized at 11%; in the meantime
the proportion of APD has increased from 9 to 43% of
all the PD patients. A recent survey made among the
19 dialysis units in the French-speaking part of
Switzerland revealed that only eight of those units
practice PD and that the percentage of PD patients
varied between 0 and 23% of their population treated
by dialysis [11].
In addition, regional disparities in the distribution of
chronic kidney disease (CKD) must also be taken into
account: a comparison between two different Swiss
cantons revealed that the canton of Vaud treated 340
dialysis patients/million inhabitants (compared to a
Swiss mean of 329), while this prevalence was at 476 in
the canton Wallis. The percentage of dialysis patients
treated by PD was at 19% in Vaud and only 6% in
Wallis [12]. This difference is partly explained by the
higher prevalence of adult polycystic kidney disease in
Wallis, a medical factor that might restrict the use of
PD but certainly does not explain the lower transplan-
tation rate. Based on this survey it appeared that, while
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patient age or co-morbidities were comparable, the
canton Wallis treated—mostly due to medical opi-
nion—fewer patients with PD and kidney transplanta-
tion, illustrating once again the role of other factors.
Interestingly, even within the PD treatment mod-
alities, the use of automated PD (APD) vs CAPD
seems to be centre- and/or region-dependent. While the
French-speaking part of Switzerland has largely moved
to APD, used in >60% of the PD patients, this trend
is less marked and more recent in the German-
speaking part (Table 1). This difference is most
probably explained by patient attitudes towards
autonomous dialysis and preferences concerning
daytime activities.
Which factors inﬂuence the use of PD?
The factors which might inﬂuence the use of PD are
given in Table 2.
Economic factors
The reimbursement rates foreseen for centre haemo-
dialysis do allow centres some ﬁnancial beneﬁt
depending on the centre type, organization and social
security regulations [1,2,10]. The same does not apply
to PD, since no reimbursement is foreseen in
Switzerland for the supervision made by the centre
staff when dialysis is practiced at home. This means
that in Switzerland at least, home therapy has until
now been a rather idealistic therapy applied by
idealistic nephrologists.
As a consequence, the vast majority of the Swiss PD
patients are treated in public centres, with only around
10 patients being treated in private centres (Table 3).
Among the 70 Swiss dialysis units, 32 practice
PD (46%), but when subdivided according to their
structure, 30 out of 51 public units (59%) and only 2
out of 19 private units (11%) practice PD.
Centre factors
It has been recognized that the individual opinion—or
bias—of the nephrologist and also of the nursing staff
plays a major role in the decision taken when they
transmit information to a patient going to start dialysis
therapy [13]. In a USRDS survey, only 25% of the HD
patients remembered having been informed about PD,
but 68% of the PD patients recalled the HD option
being discussed with them [14]. The dialysis modality
distribution is also very heterogeneous between and
within several countries [15]. When asked about their
personal opinion on the optimal dialysis technique
mix, Canadian nephrologists gave numbers around
37% for PD that corresponded to their real practice
[16]; American nephrologists in contrast thought that
Table 2. Non-medical reasons that inﬂuence PD utilization
1. Financial factors
Reimbursement rates
2. Centre factors
Dialysis staff opinion or bias
PD experience
HD availability
3. Patient factors
Opinion of primary care physician
Distance to the unit
Availability of dialysis partner
Timing of nephrological referral
4. Socio-economic factors
Structure of dialysis program
Number of dialysis centres
5. Cultural factors
Attitude towards chronic disease
Attitude towards home therapy
Fig. 1 Evolution of the number of chronic dialysis patients in
Switzerland from 1993 to 2003 according to treatment type. HD,
haemodialysis; APD, any form of automated peritoneal dialysis;
CAPD, continuous ambulatory peritoneal dialysis.
Table 1. Evolution of the use of PD and automated PD in
Switzerland according to linguistic regions
1998 1999 2000 2001 2002
French-speaking part
PD as % of dialysis patients 12.1 10.6 10.4 10.2 10.6
Automated PD (%PD) 58.5 61.4 56.8 60.5 62.4
German-speaking part
PD as % of dialysis patients 12.2 13.0 12.6 12.0 11.8
Automated PD (%PD) 14.0 21.7 26.8 29.9 35.4
Table 3. Evolution of the number of dialysis patients in
Switzerland according to the centre structure
1998 1999 2000 2001 2002
HD public centres 1583 1600 1659 1708 1793
HD private centres 299 315 400 439 484
PD public centres 256 259 271 267 280
PD private centres 5 9 8 10 14
Total 2143 2183 2338 2424 2571
1364 Nephrol Dial Transplant (2004) 19: Editorial Comments
31% of PD would be ideal while the actual number
was 14% [17].
Along the same lines, HD will be systematically
favoured when insufﬁcient professional experience in
the PD technology is at hand. This will be even more
the case when a HD centre structure and trained staff
are available: the marginal cost of a new additional
patient will automatically favour the technique most at
hand. With 70 centres for a population of 7.5 million
inhabitants, Switzerland has one of the highest dialysis
centre densities in the world. The unexpected increase
in CAPD patient numbers seen in 2002 was probably
due to the fact that two large dialysis units were
overcrowded and faced with an acute problem of
unavailable haemodialysis posts.
Patient factors
Even when objectively oriented by the nephrology
staff, some pre-existing patient factors may also
inﬂuence their ﬁnal choice. Previous information
given by the primary care physician or another
nephrologist might play a fundamental role, but
other factors must also be considered: travel distance
to the unit, socio-familial factors such as presence of a
spouse or housing facilities, and more individual
factors such as age, education, profession and co-
morbidities [18]. Patient preferences may also be
inﬂuenced by totally dialysis-free days, daytime activ-
ities or body image. Within a group of 150 consecutive
patients starting dialysis, Prichard [7] illustrated that
among the 84 who were not treated by one of the
techniques for preferential medical or social reasons,
37 chose PD and 37 HD; among the latter, 15 ﬁnally
performed self- or home-therapy, 7 had previously
been treated by HD, 4 refused PD and 11 were late
referrals to the dialysis unit.
The deleterious effect of late referral on the
preferential choice of HD has been demonstrated
repeatedly [19–21]. Blake [10] has shown that, in his
unit, of 161 consecutive new ESRF patients, 22% were
treated by PD, but this percentage rose to 32% for
those who had received previous information, and was
only 4% when this information could not have been
given.
In their European multi-centre survey, Lameire et al.
[22] demonstrated that in patients referred late, HD is
chosen much more often than among those who are
referred early. This observation, however, was not
made in 4 of the 13 centres, illustrating again that this
therapeutic choice is a multi-factorial process.
Socio-economic factors
The structure of the dialysis program within any given
country or region and/or the dialysis infrastructure
and stafﬁng at hand in any particular centre may also
inﬂuence the development of any given technique. In
most units, it is easier to start an additional patient
on an existing HD post than to go through the more
time- and staff-consuming procedure of PD training.
Cultural factors
Finally, the place of an autonomous therapy may also
be inﬂuenced by persistent or changing cultural atti-
tudes towards the chronic disease state. This factor
explains why home therapy is almost non-existent in
Japan and may also partly elucidate the changing
pattern observed in Europe [23].
Some proposals towards a more homogeneous use
All possible therapy options should be offered to any
patient with ESRD. However, the nephrologist should
not ignore the economic burden placed by dialysis
treatment programmes on social security systems. In
all cost evaluations made, centre HD appears as the
most expensive treatment modality [3,10]. It is there-
fore our duty to prevent all potential bias that
interferes with therapeutic choices when expensive
options are chosen.
Social security measures
The reimbursement rate of the autonomous dialysis
treatment modalities should not penalize those thera-
pies. While a ﬁnancial proﬁt can be made today with
most of the present reimbursement rates for centre
dialysis, autonomous therapies usually result in a loss
of money for the dialysis unit. A fee for the setting-up
and running of an autonomous dialysis program in
addition to the patient regular consultations and
back-up should be implemented. On the other hand,
reimbursement of the workload assumed by the patient
or his eventual dialysis partner should also be taken
into account.
An evaluation of the global costs (instead of the
dialysis technique costs) will also provide better
comparative data: the inclusion of hospitalization
costs, travel time to the unit, additional costs of surgery
and drugs, paying-off of dialysis equipment, personnel
salaries, etc will allow a more precise comparison than
the net dialysis reimbursement rates [24].
Educational measures
In order to better inform their patients about all
existing ESRD therapeutic possibilities, primary care
physicians as well as nephrologists should receive a
more detailed education at the pre-, post- and
continuous-education level. As yet, the advantages,
indications and contra-indications of ESRD therapy
options are seldom part of the general medical teaching
programs. The same applies to most of the nurses
training programs. In several units, PD prescription is
done mostly by the PD nurses with little involvement of
the nephrologist; and the increased complexity of the
newer PD techniques [25] will not necessarily facilitate
more medical commitment. Recently, Schaubel et al.
[26] have shown that a centre’s experience and degree
of specialization toward PD strongly impact on PD
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outcome. Therefore, the PD curriculum set-up by the
International Society for Peritoneal Dialysis should
become an integrated part of all nephrological training
programs at the postgraduate level [27]. It might also be
questioned whether nephrologists should receive an
education in health economics, taking into account the
tremendous but difﬁcult to evaluate expenses necessi-
tated by the ESRF programs in each country [24,28].
Patient information measures
An integrated collaboration between primary care
physicians and nephrologists should be set up to
prevent the late referral pattern and allow not only
better treatment of the progressing CKD and its
complications but also more complete and objective
informing of the patients and their families
[20,21,29,30]. This information should be adapted to
the patient and his family at all levels of progressive
CKD depending on their level of understanding and
also on the progression rate of their CKD: patients do
not need to be informed about the respective advan-
tages of dialysis therapies when they have an almost
stable or still very moderate decline in their kidney
function.
The advantages of a multidisciplinary approach
involving other para-medical professions and other
patients have already been demonstrated [29].
PD logistics measures
PD utilization should not be hampered by barriers
such as insufﬁcient stockpiling space from infrequent
material delivery or transient partner unavailability.
The availability of para-medical personnel at home or
in nursing homes for transient help and advice has
proven very useful [31]. The development of efﬁcient
and easy-to-use APD cyclers may also convince more
patients to tackle the burden of autonomous therapy
by not spending much day time for exchanges and
making training and daily use less demanding. Finally,
better prevention or treatment of the side-effects or
complications of PD therapy (peritonitis prevention,
more biocompatible dialysis solutions, etc) will also
provide better long-term use.
Conclusions
It is a challenge to the nephrological community to
offer the best options in all aspects of dialysis and
transplant therapies to patients with ESRF at a cost
that remains within the possibilities of health care
budgets. Several non-medical factors presently inter-
fere with the prescription of dialysis therapies. Most of
those factors tend to favour centre haemodialysis.
Steps towards a more homogeneous PD utilization
have been identiﬁed. Their implementation necessitates
measures to be implemented at three levels: national
(social security measures, reimbursement rates),
regional (pre- and post-graduate education) and
centre stage (education and communication, logistics).
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